Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.
The British Journal of Psychiatry November 1, 2024 Gero Joks, Steve Su, Jarrad King
Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial', we commend Loo et al for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare...
DOI: 10.1192/bjp.2024.79 (opens in new tab)
Full text (opens in new tab)
Major depressive disorder
Depression/mental health/mental illness
Ketamine/esketamine/psychedelics
Treatment-resistant depression/trd/refractory depression